Q1 Earnings Estimate for VRDN Issued By Wedbush

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Wedbush issued their Q1 2026 earnings per share estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst L. Chico anticipates that the company will earn ($1.17) per share for the quarter. Wedbush currently has a “Outperform” rating and a $42.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2028 earnings at $9.52 EPS.

A number of other equities analysts have also weighed in on the stock. BTIG Research boosted their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. The Goldman Sachs Group increased their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 price target (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.50.

Viridian Therapeutics Stock Up 0.6 %

NASDAQ:VRDN traded up $0.14 on Thursday, reaching $22.62. 45,552 shares of the stock traded hands, compared to its average volume of 1,110,581. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -5.22 and a beta of 1.10. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The company’s fifty day simple moving average is $22.35 and its 200 day simple moving average is $16.89.

Institutional Trading of Viridian Therapeutics

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC grew its holdings in shares of Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after purchasing an additional 4,692 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after buying an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after buying an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC raised its position in shares of Viridian Therapeutics by 108.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after buying an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after acquiring an additional 1,688 shares during the last quarter.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, COO Thomas W. Beetham bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now owns 6,000 shares of the company’s stock, valued at $140,460. This trade represents a 500.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Thomas W. Beetham bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. The trade was a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Stephen F. Mahoney purchased 21,400 shares of Viridian Therapeutics stock in a transaction on Friday, September 27th. The stock was bought at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the acquisition, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,626,400 shares of company stock valued at $30,616,312 over the last ninety days. 0.65% of the stock is currently owned by company insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.